Rare Lymphoma Risk Haunts Remicade Expansion To Pediatric Ulcerative Colitis

Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.